DK3027656T3 - Medikament, der omfatter anti-phospholipase d4-antistof - Google Patents

Medikament, der omfatter anti-phospholipase d4-antistof Download PDF

Info

Publication number
DK3027656T3
DK3027656T3 DK14761423.4T DK14761423T DK3027656T3 DK 3027656 T3 DK3027656 T3 DK 3027656T3 DK 14761423 T DK14761423 T DK 14761423T DK 3027656 T3 DK3027656 T3 DK 3027656T3
Authority
DK
Denmark
Prior art keywords
phospholipase
antibody
containing anti
medication containing
medication
Prior art date
Application number
DK14761423.4T
Other languages
Danish (da)
English (en)
Inventor
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
Sbi Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sbi Biotech Co Ltd filed Critical Sbi Biotech Co Ltd
Application granted granted Critical
Publication of DK3027656T3 publication Critical patent/DK3027656T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK14761423.4T 2013-07-30 2014-07-30 Medikament, der omfatter anti-phospholipase d4-antistof DK3027656T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Publications (1)

Publication Number Publication Date
DK3027656T3 true DK3027656T3 (da) 2019-08-05

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14761423.4T DK3027656T3 (da) 2013-07-30 2014-07-30 Medikament, der omfatter anti-phospholipase d4-antistof

Country Status (17)

Country Link
US (2) US20160168266A1 (enExample)
EP (1) EP3027656B1 (enExample)
JP (3) JP6431523B2 (enExample)
KR (1) KR102367760B1 (enExample)
CN (1) CN105745226B (enExample)
AU (1) AU2014297217B2 (enExample)
BR (1) BR112016002001B1 (enExample)
CA (1) CA2919736C (enExample)
DK (1) DK3027656T3 (enExample)
ES (1) ES2736324T3 (enExample)
HU (1) HUE044469T2 (enExample)
MX (1) MX381725B (enExample)
PL (1) PL3027656T3 (enExample)
RU (1) RU2709741C2 (enExample)
SG (2) SG11201600666SA (enExample)
TR (1) TR201910330T4 (enExample)
WO (1) WO2015016386A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
SG11201600666SA (en) * 2013-07-30 2016-02-26 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型tlr7の分析

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE139900T1 (de) * 1992-11-13 1996-07-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
WO2000011015A1 (en) * 1998-08-24 2000-03-02 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
EP1392855A4 (en) * 2000-12-07 2005-05-25 Millennium Pharm Inc METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
HUE054362T2 (hu) * 2012-01-31 2021-09-28 Sbi Biotech Co Ltd Foszfolipáz D4 elleni antitest
SG11201600666SA (en) * 2013-07-30 2016-02-26 Sbi Biotech Co Ltd Medicament comprising anti-phospholipase d4 antibody

Also Published As

Publication number Publication date
JP6843449B2 (ja) 2021-03-17
JP2019014759A (ja) 2019-01-31
BR112016002001B1 (pt) 2023-04-25
CA2919736C (en) 2022-03-22
JP2016534022A (ja) 2016-11-04
CN105745226B (zh) 2020-03-06
HUE044469T2 (hu) 2019-10-28
RU2709741C2 (ru) 2019-12-19
RU2016106708A3 (enExample) 2018-03-30
PL3027656T3 (pl) 2019-10-31
US20160168266A1 (en) 2016-06-16
ES2736324T3 (es) 2019-12-27
RU2016106708A (ru) 2017-09-01
KR102367760B1 (ko) 2022-02-24
AU2014297217B2 (en) 2020-01-16
KR20160034934A (ko) 2016-03-30
SG11201600666SA (en) 2016-02-26
JP2019214621A (ja) 2019-12-19
BR112016002001A2 (pt) 2017-08-29
TR201910330T4 (tr) 2019-07-22
EP3027656B1 (en) 2019-06-26
EP3027656A1 (en) 2016-06-08
SG10201800592SA (en) 2018-03-28
US20210130493A1 (en) 2021-05-06
MX381725B (es) 2025-03-13
MX2016001193A (es) 2016-05-26
CA2919736A1 (en) 2015-02-05
JP6431523B2 (ja) 2018-11-28
CN105745226A (zh) 2016-07-06
AU2014297217A1 (en) 2016-02-18
WO2015016386A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
FR3006466B3 (fr) .
FR3013601B1 (fr) Autoinjecteur.
FR3007989B1 (fr) Autoinjecteur.
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
SG11201600666SA (en) Medicament comprising anti-phospholipase d4 antibody
FR3001302B1 (fr) .
ES1086107Y (es) Contenedor armable.
FR3001303B1 (fr) .
BR302013006684S1 (pt) Configuração aplicada em garrafa.
BR302013002358S1 (pt) Configuração aplicada em frasco.
TH148359B (th) ไพรโรลิดีน-2-คาร์บอกซาไมด์ที่ถูกแทนที่
UA27144S (uk) Пляшка
UA26504S (uk) Пляшка
UA26588S (uk) Пляшка
UA26699S (uk) Пляшка
ITBS20130045U1 (it) Bottiglia barrique
UA27140S (uk) Пляшка
UA26297S (uk) Пляшка
UA28063S (uk) Пляшка
UA27836S (uk) Пляшка
UA27824S (uk) Пляшка
UA26130S (uk) Пляшка
UA27562S (uk) Пляшка
UA25509S (uk) Пляшка